Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported 2025 results and a business update on Mar 26, 2026, highlighting clinical progress for sabirnetug and advancement of an Enhanced Brain Delivery (EBD) program.
Key items: $35.75M private placement for EBD candidates, $116.9M cash as of Dec 31, 2025 (runway into early 2027), topline ALTITUDE-AD Phase 2 results expected late 2026, and an IND target for an EBD lead candidate in mid-2027. R&D spend rose to $104.9M; net loss was $121.3M for 2025.
Acumen Pharmaceuticals (NASDAQ: ABOS) will report fourth quarter and year-end 2025 financial results on March 26, 2026 and will host a conference call and live audio webcast at 8:00 a.m. ET.
According to the company, registration is required for dial-in details, the live webcast link is provided, and an archived webcast will be available for at least 30 days in Investors on www.acumenpharm.com.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new preclinical and biomarker data at AD/PD 2026 (March 17-21) on enhanced brain delivery, NULISAseq biomarker profiling, and novel anti-amyloid beta oligomer antibodies. Key findings: TfR-targeted bispecifics increased sabirnetug brain exposure, NULISAseq measured 127 CNS proteins, and ACU234 showed ~21,000-fold oligomer selectivity.
The data support further characterization and integration with ongoing Phase 2 ALTITUDE‑AD and prior Phase 1 INTERCEPT‑AD results.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced a $35.75 million private placement at $3.30 per share to fund its Enhanced Brain Delivery (EBD™) program and general corporate purposes, with closing expected on or about March 16, 2026.
Preclinical EBD data show development candidates achieved 14–40x higher brain exposure in non-human primates, low anemia signal in hematology, stability supporting subcutaneous dosing, and an IND target of mid-2027.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Wednesday, March 18, 2026 at 11:00 a.m. ET. The company is a clinical-stage biopharmaceutical developer targeting toxic soluble amyloid beta oligomers for Alzheimer’s disease. The live webcast is available under the Investors tab on the company website and will be archived for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) will present one oral and two poster presentations at the AD/PD conference in Copenhagen, March 17–21, 2026. Presentations cover enhanced brain delivery (EBD™) of sabirnetug, sabirnetug biomarker responses (NULISA-Seq-TM), and novel AβO-targeting antibodies.
The oral talk on March 21 details fusion of sabirnetug with an anti-transferrin receptor fragment; posters on March 17–18 cover biomarker analytics and antibody characterization. The oral data arise from an ongoing collaboration with JCR Pharmaceuticals using J-Brain Cargo® technology and support analytic plans for Phase 2 ALTITUDE‑AD.
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new preclinical and clinical-trial recruitment data at the 18th Annual CTAD conference on December 1-4, 2025. A collaborative study with JCR Pharmaceuticals showed that fusing transferrin receptor (TfR) binders to AβO-targeting antibodies (including sabirnetug/ACU193) produced 15–68 fold increases in brain penetration in mice while preserving target binding. Acumen and JCR are developing TfR-targeting antibodies for clinical testing. Recruitment analysis from the Phase 2 ALTITUDE-AD trial tracked 2,362 screened across 76 sites with 542 enrolled, finding site databases and physician referrals were the most reliable recruitment methods.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced on Nov 17, 2025 that the first participant was dosed in the open-label extension (OLE) of its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in people with early Alzheimer’s disease.
The OLE offers participants who completed the 18-month placebo-controlled portion additional dosing of 35 mg/kg IV every four weeks for 52 weeks. Clinical measures and safety monitoring remain the same. The company cited Phase 1 INTERCEPT-AD results showing favorable safety, low ARIA-E rates, target engagement, and biomarker effects including amyloid plaque reduction at highest doses. Acumen expects topline ALTITUDE-AD results in late 2026.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q3 2025 results and a business update on Nov. 12, 2025. The company had $136.1 million in cash, cash equivalents and marketable securities as of Sept. 30, 2025, which it expects will support operations into early 2027. Acumen continues its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) and began dosing the open-label extension in Nov. 2025. The company expects non-clinical data for its Enhanced Brain Delivery program in early 2026 and Phase 2 topline results for ALTITUDE-AD in late 2026. Q3 R&D expense was $22.0M and net loss was $26.5M.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced that George Golumbeski, Ph.D. has been appointed Chairman of its Board of Directors, bringing more than 30 years of biopharma experience.
The Board now totals eight members. Management highlighted Golumbeski’s expertise in portfolio strategy, collaborations, licensing and M&A and said his experience aligns with anticipated catalysts next year for Acumen’s Phase 2 sabirnetug trial and its Enhanced Brain Delivery program.